Therefore, we hypothesized that in-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for rapid and effective detection of predictive biomarkers (i.e., including RET) in patients with NSCLC. Here, RET is linked to non-small cell lung carcinoma.